| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/28/2026 | ±2.2% | +4.0% | under-priced |
| 04/28/2026 | ±2.0% | -4.5% | under-priced |
| 10/28/2025 | ±1.3% | +0.7% | over-priced |
| 07/31/2025 | ±1.4% | +10.7% | under-priced |
| 04/29/2025 | ±2.7% | +2.3% | over-priced |
| 10/31/2024 | ±1.4% | -6.5% | under-priced |
| 07/30/2024 | ±2.6% | -5.7% | under-priced |
| 05/02/2024 | ±2.1% | +3.8% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.11 | $2.3B | $261M |
| Q1 FY2026 | $0.79 | $2.1B | $189M |
| Q4 FY2025 | $1.37 | $2.4B | $333M |
| Q3 FY2025 | $0.93 | $2.3B | $226M |
Xylem Inc (XYL) reports in 72 days, with the next report estimated for 11/18/2026. Across the last 8 reports, options priced an average ±2.0% earnings move while the stock actually moved 4.8% on average — the market has tended to under-price XYL's earnings risk. Fundamentals into the print: EPS up 19.4% year-over-year, revenue up 1.5%. QuantLogix's live 5-factor engine currently reads XYL as a underweight at 16/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →